Technical Analysis for CELG - Celgene Corporation
|Grade||Last Price||% Change||Price Change|
CELG closed up 0.64 percent on Thursday, June 22, 2017, on 2.21 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Trend Table & Recent Alerts
|See historical CELG trend table...|
|Date||Alert Name||Type||% Chg|
|Jun 22||New 52 Week High||Bullish||0.00%|
|Jun 22||Upper Bollinger Band Walk||Other||0.00%|
|Jun 22||Calm After Storm||Range Contraction||0.00%|
|Jun 21||New 52 Week High||Bullish||0.64%|
|Jun 21||Volume Surge||Other||0.64%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Its commercial stage products include REVLIMID, a drug to treat multiple myeloma and transfusion-dependent anemia; VIDAZA, a nucleoside analog to treat intermediate-2 and myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML); ABRAXANE, a chemotherapy treatment option for metastatic breast cancer; and THALOMID for multiple myeloma and the cutaneous manifestations of erythema nodosum leprosum. The company's commercial stage products also comprise ISTODAX to treat cutaneous T-cell lymphoma; POMALYST for the multiple myeloma and myelofibrosis treatment; and FOCALIN, FOCALIN XR, and RITALIN LA products. Its pre clinical and clinical stage products consist of CC-11050, an anti-inflammatory compound; CC-220, an anti-inflammatory product; cellular therapies, such as PDA-001 and PDA-002; CC-486 that is in Phase III trials to treat MDS and AML, as well as in a Phase I trials for solid tumor indications; and sotatercept and ACE-536, which are in Phase II trials to treat anemia. The company's pre clinical and clinical stage products also include CC-223, a dual TORK inhibitor; CC-292, a BTK inhibitor; CC-115, a dual TORK/DNA PK inhibitor; CC-122, a pleiotropic pathway modulator; and EPZ-5676, a DOT1L inhibitor. It has strategic collaborations with bluebird bio, Inc.; FORMA Therapeutics Holdings; Concert Pharmaceuticals, Inc.; Array BioPharma, Inc.; and Acetylon Pharmaceuticals, Inc., as well as a strategic alliance with MorphoSys AG. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Is CELG a Buy, Sell or Hold?
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CELG news...
|52 Week High||135.18|
|52 Week Low||94.42|
|200-Day Moving Average||116.4254|
|50-Day Moving Average||121.013|
|20-Day Moving Average||120.3435|
|10-Day Moving Average||123.906|
|Average True Range||2.5667|
|Chandelier Exit (Long, 3 ATRs)||127.4799|
|Chandelier Exit (Short, 3 ATRs)||121.3301|
|Upper Bollinger Band||130.7735|
|Lower Bollinger Band||109.9135|
|Percent B (%b)||1.14|
|MACD Signal Line||0.8367|